These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Impact of prostate gland volume on cryoablation prostate-specific antigen outcomes. Levy DA; Jones JS Urology; 2011 Apr; 77(4):994-8. PubMed ID: 21333336 [TBL] [Abstract][Full Text] [Related]
4. Disease burden predicts for favorable post salvage cryoablation PSA. Levy DA; Li J; Jones JS Urology; 2010 Nov; 76(5):1157-61. PubMed ID: 20381837 [TBL] [Abstract][Full Text] [Related]
10. Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Cohen JK; Miller RJ; Ahmed S; Lotz MJ; Baust J Urology; 2008 Mar; 71(3):515-8. PubMed ID: 18342200 [TBL] [Abstract][Full Text] [Related]
11. Should cryosurgery be considered a therapeutic option in localized prostate cancer? Connolly JA; Shinohara K; Presti JC; Carroll PR Urol Clin North Am; 1996 Nov; 23(4):623-31. PubMed ID: 8948416 [TBL] [Abstract][Full Text] [Related]
12. Best practice statement on cryosurgery for the treatment of localized prostate cancer. Babaian RJ; Donnelly B; Bahn D; Baust JG; Dineen M; Ellis D; Katz A; Pisters L; Rukstalis D; Shinohara K; Thrasher JB J Urol; 2008 Nov; 180(5):1993-2004. PubMed ID: 18817934 [No Abstract] [Full Text] [Related]
13. Editorial comment on: Prostate-specific antigen improves the ability of clinical stage and biopsy gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. Stenman UH Eur Urol; 2007 Oct; 52(4):1074-5. PubMed ID: 17383813 [No Abstract] [Full Text] [Related]
14. The efficacy of cryosurgical ablation of prostate cancer: the University of California, San Francisco experience. Koppie TM; Shinohara K; Grossfeld GD; Presti JC; Carroll PR J Urol; 1999 Aug; 162(2):427-32. PubMed ID: 10411051 [TBL] [Abstract][Full Text] [Related]
15. Predicting biopsy-proven prostate cancer recurrence following cryosurgery. Caso JR; Tsivian M; Mouraviev V; Polascik TJ Urol Oncol; 2012; 30(4):391-5. PubMed ID: 20826095 [TBL] [Abstract][Full Text] [Related]
16. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. Han KR; Cohen JK; Miller RJ; Pantuck AJ; Freitas DG; Cuevas CA; Kim HL; Lugg J; Childs SJ; Shuman B; Jayson MA; Shore ND; Moore Y; Zisman A; Lee JY; Ugarte R; Mynderse LA; Wilson TM; Sweat SD; Zincke H; Belldegrun AS J Urol; 2003 Oct; 170(4 Pt 1):1126-30. PubMed ID: 14501706 [TBL] [Abstract][Full Text] [Related]
17. Prostate cryoablation: prospective analysis comparing high- and low-risk prostate cancer outcomes. El Hayek OR; Alfer W; Reggio E; Pompeo AC; Arap S; Lucon AM; Srougi M Urol Int; 2008; 81(2):186-90. PubMed ID: 18758217 [TBL] [Abstract][Full Text] [Related]
18. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Kurhanewicz J; Vigneron DB; Hricak H; Parivar F; Nelson SJ; Shinohara K; Carroll PR Radiology; 1996 Aug; 200(2):489-96. PubMed ID: 8685346 [TBL] [Abstract][Full Text] [Related]
19. PSA elevation during prostate cryosurgery and subsequent decline. Leibovici D; Zisman A; Lindner A; Stav K; Siegel YI Urol Oncol; 2005; 23(1):8-11. PubMed ID: 15885576 [TBL] [Abstract][Full Text] [Related]
20. Men with organ-confined prostate cancer and positive surgical margins develop biochemical failure at a similar rate to men with extracapsular extension. Psutka SP; Feldman AS; Rodin D; Olumi AF; Wu CL; McDougal WS Urology; 2011 Jul; 78(1):121-5. PubMed ID: 21411125 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]